US 11,911,385 B1
Methotrexate treatment methods
Stephen Gitu Machatha, Wilmington, MA (US); Dean Eliott, Carlsbad, CA (US); and Tomasz Stryjewski, Somerville, MA (US)
Assigned to ALDEYRA THERAPEUTICS, INC., Lexington, MA (US)
Filed by Aldeyra Therapeutics, Inc., Lexington, MA (US)
Filed on Dec. 14, 2022, as Appl. No. 18/081,546.
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61P 27/02 (2006.01); A61K 47/26 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 47/26 (2013.01); A61P 27/02 (2018.01)] 20 Claims
OG exemplary drawing
 
1. A method of treating retinitis pigmentosa (RP), comprising administering intravitreally to a subject in need thereof a composition comprising methotrexate at a concentration of about 5 mg/mL to about 12 mg/mL; sucrose at a concentration of about 7% w/v to about 12% w/v; and a phosphate buffer; wherein the volume of composition administered is about 20 μL to about 300 μL wherein the composition is administered for inhibiting and relieving retinitis pigmentosa and the incidence of secondary punctate keratitis in the subject is reduced by about 10% to 50% compared to a similar subject administered a non-GMP composition of methotrexate or a composition comprising methotrexate in a volume greater than 300 μL.